Intas Pharmaceuticals recently launched Razumab, a biosimilar to Lucentis, which is used to treat degenerative conditions of the eye and would be 25 percent cheaper than the originator therapy, Business Standard reported.
"Intas' Razumab is a 100 percent 'Made In India' molecule, a feat achieved by the scientists at Intas. With the mission to provide global healthcare at affordable costs, Razumab will be about 25 per cent cheaper than the imported Lucentis in the hand of the patient. This would lead to an annual saving of about Rs. 35,000 or more in the cost of treatment to the patient, depending on the number of injections used and the clinical condition of the patient," said Binish Chudgar, vice chairman of the company.
Razumab is the tenth biosimilar launched by Intas in India and Intas is also the only company from India to have launched a biosimilar in the highly regulated European market and is also the only company from India to have two of its biosimilars filed for registration in the US.